We are live on
!
Find out more
FAF
Fjarde Ap-fonden Portfolio holdings
AUM
$20.9B
1-Year Est. Return
36.93%
This Fund
S&P 500
This Quarter
Est. Return
+25.08%
1 Year Est. Return
+36.93%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.97B
AUM Growth
+$1.75B
(+28%)
Cap. Flow
+$349M
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
26.82%
Holding
643
New
25
Increased
368
Reduced
201
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI USA Value Factor ETF
VLUE
|
+$64.9M |
| 2 |
Microsoft
MSFT
|
+$13.9M |
| 3 |
Amazon
AMZN
|
+$11.6M |
| 4 |
AbbVie
ABBV
|
+$9.54M |
| 5 |
Illinois Tool Works
ITW
|
+$8.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$19.6M |
| 2 |
AGN
Allergan plc
AGN
|
+$16.2M |
| 3 |
Eli Lilly
LLY
|
+$13M |
| 4 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$5.8M |
| 5 |
Bank of America
BAC
|
+$3.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.9% |
| 2 | Healthcare | 14.53% |
| 3 | Financials | 12.89% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tesla
TSLA
$1.23T
| $54.6M | 0.69% |
758,760
+48,000
| +7% | +$2.6M |
|
27
Coca-Cola
KO
$377B
| $53.8M | 0.67% |
1,203,416
+71,600
| +6% | +$3.3M |
|
|
28
Bank of America
BAC
$435B
| $53.5M | 0.67% |
2,253,565
-136,900
| -6% | -$3.23M |
|
29
Pfizer
PFE
$143B
| $53.2M | 0.67% |
1,714,659
+86,217
| +5% | +$2.93M |
|
30
PepsiCo
PEP
$190B
| $52.3M | 0.66% |
395,330
+26,700
| +7% | +$3.52M |
|
31
Comcast
CMCSA
$85B
| $51.6M | 0.65% |
1,322,648
+43,500
| +3% | +$1.66M |
|
|
32
AbbVie
ABBV
$443B
| $51.2M | 0.64% |
521,676
+108,397
| +26% | +$9.54M |
|
33
Chevron
CVX
$392B
| $49M | 0.61% |
548,682
+18,700
| +4% | +$1.67M |
|
34
Salesforce
CRM
$151B
| $45.9M | 0.58% |
244,797
+10,100
| +4% | +$1.7M |
|
35
Intel
INTC
$455B
| $44.7M | 0.56% |
746,313
+40,160
| +6% | +$2.4M |
|
36
Thermo Fisher Scientific
TMO
$213B
| $43.2M | 0.54% |
119,176
+6,100
| +5% | +$2.04M |
|
37
Amgen
AMGN
$208B
| $41.3M | 0.52% |
175,245
+7,500
| +4% | +$1.71M |
|
38
McDonald's
MCD
$192B
| $40.1M | 0.5% |
217,162
+7,700
| +4% | +$1.41M |
|
39
Costco
COST
$422B
| $39.2M | 0.49% |
129,440
+7,000
| +6% | +$2.13M |
|
40
Bristol-Myers Squibb
BMY
$133B
| $39.1M | 0.49% |
664,955
+10,700
| +2% | +$640K |
|
41
Accenture
ACN
$102B
| $39M | 0.49% |
181,494
+6,800
| +4% | +$1.29M |
|
42
Broadcom
AVGO
$1.85T
| $38.1M | 0.48% |
1,207,560
+37,000
| +3% | +$1.04M |
|
43
Oracle
ORCL
$374B
| $37.7M | 0.47% |
681,713
+5,100
| +0.8% | +$270K |
|
44
Berkshire Hathaway Class B
BRK.B
$1.1T
| $37.3M | 0.47% |
209,020
+43,300
| +26% | +$7.91M |
|
45
Nike
NKE
$61.9B
| $36M | 0.45% |
367,661
+14,000
| +4% | +$1.29M |
|
46
Medtronic
MDT
$109B
| $35.9M | 0.45% |
391,862
+16,000
| +4% | +$1.53M |
|
47
Danaher
DHR
$137B
| $33.5M | 0.42% |
213,936
+16,130
| +8% | +$2.31M |
|
48
American Tower
AMT
$80.8B
| $33.3M | 0.42% |
128,625
+8,000
| +7% | +$1.98M |
|
|
49
ExxonMobil
XOM
$644B
| $33M | 0.41% |
737,908
-436,692
| -37% | -$19.6M |
|
50
IBM
IBM
$211B
| $32.9M | 0.41% |
285,295
+15,339
| +6% | +$1.78M |
|
Similar funds
MMH
VARA
SC
CB
MIC
GT
Fjarde Ap-fonden's Q2 2020 Portfolio in Review
As of Q2 2020, Fjarde Ap-fonden held 643 positions worth $7.97B, up 28% from $6.21B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Fjarde Ap-fonden deployed $349M of net new capital in Q2 2020, opening 25 new positions and adding to 368 existing holdings. Its largest new stake was iShares MSCI USA Value Factor ETF: 931,000 shares worth $67.3M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was ExxonMobil, an estimated $19.6M trimmed.
- Fjarde Ap-fonden's largest Q2 2020 buy was iShares MSCI USA Value Factor ETF: 931,000 shares worth $67.3M.
- Fjarde Ap-fonden added most to Microsoft in Q2 2020, an estimated $13.9M increase.
- Fjarde Ap-fonden's biggest Q2 2020 reduction was ExxonMobil, cutting an estimated $19.6M.
- Fjarde Ap-fonden fully exited Allergan plc in Q2 2020, selling an estimated $16.2M.
- Fjarde Ap-fonden's ten largest holdings make up 27% of its $7.97B portfolio in Q2 2020.
- Fjarde Ap-fonden opened 25 new positions and closed 37 in Q2 2020.
- Fjarde Ap-fonden's portfolio value rose 28% quarter-over-quarter to $7.97B.
Based on Fjarde Ap-fonden's 13F filing for Q2 2020, filed 13 Aug 2020.